Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets

Journal of Virology

Volumn 84, Issue 19, 2010, Pages 10366-10374

  Bosch, Berend Jan ^a   Bodewes, Rogier ^b   De Vries, Robert P ^a   Kreijtz, Joost H C M ^b   Bartelink, Willem ^a   Van Amerongen, Geert ^b   Rimmelzwaan, Guus F ^b   De Haan, Cornelis A M ^a   Osterhaus, Albert D M E ^b   Rottier, Peter J M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; SIALIDASE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FERRET; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INOCULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SWINE INFLUENZA; VIRUS REPLICATION; WEIGHT REDUCTION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; CROSS REACTION; DISEASE OUTBREAKS; HUMAN; IMMUNOLOGY; INFLUENZA, HUMAN; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; SOLUBILITY; SWINE; VIROLOGY;

INFLUENZAVIRUS A; MAMMALIA; MUSTELA; ORTHOMYXOVIRIDAE; SUIDAE;

ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; DISEASE OUTBREAKS; FEMALE; FERRETS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG; MODELS, ANIMAL; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN MULTIMERIZATION; SOLUBILITY; SWINE; VACCINES, SYNTHETIC; VIRUS REPLICATION;

EID: 77956837160     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01035-10     Document Type: Article

References (44)

1. Abed, Y., I. Hardy, Y. Li, and G. Boivin. 2002. Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada. J. Med. Virol. 67:589-595.
2. Brett, I. C., and B. E. Johansson. 2005. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 339:273-280.
3. Chen, Z., K. Matsuo, H. Asanuma, H. Takahashi, T. Iwasaki, Y. Suzuki, C. Aizawa, T. Kurata, and S. Tamura. 1999. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin-and neuraminidase-expressing DNAs. Vaccine 17:653-659. (Pubitemid 29074718)
4. Cornelissen, L. A., R. P. de Vries, E. A. de Boer-Luijtze, A. Rigter, P. J. Rottier, and C. A. de Haan. 2010. A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1. PLoS One 5:e10645.
5. Cox, M. M. 2008. Progress on baculovirus-derived influenza vaccines. Curr. Opin. Mol. Ther. 10:56-61.
6. de Jong, J. C., P. P. Heinen, W. L. Loeffen, A. P. van Nieuwstadt, E. C. Claas, T. M. Bestebroer, K. Bijlsma, C. Verweij, A. D. Osterhaus, G. F. Rimmelzwaan, R. A. Fouchier, and T. G. Kimman. 2001. Antigenic and molecular heterogeneity in recent swine influenza A(H1N1) virus isolates with possible implications for vaccination policy. Vaccine 19:4452-4464.
7. Del Giudice, G., K. J. Stittelaar, G. van Amerongen, J. Simon, A. D. Osterhaus, K. Stohr, and R. Rappuoli. 2009. Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci. Transl. Med. 1:12re1.
8. Deroo, T., W. M. Jou, and W. Fiers. 1996. Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 14:561-569.
9. de Vries, R. P., E. de Vries, B. J. Bosch, R. J. de Groot, P. J. Rottier, and C. A. de Haan. 2010. The influenza A virus hemagglutinin glycosylation state affects receptor-binding specificity. Virology 403:17-25.
10. Durocher, Y., and M. Butler. 2009. Expression systems for therapeutic glycoprotein production. Curr. Opin. Biotechnol. 20:700-707.
11. Frank, A. L., J. Puck, B. J. Hughes, and T. R. Cate. 1980. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J. Clin. Microbiol. 12:426-432.
12. Harbury, P. B., T. Zhang, P. S. Kim, and T. Alber. 1993. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262:1401-1407.
13. Huber, V. C., and J. A. McCullers. 2008. FluBlok, a recombinant influenza vaccine. Curr. Opin. Mol. Ther. 10:75-85.
14. Johansson, B. E. 1999. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 17:2073-2080.
15. Johansson, B. E., and I. C. Brett. 2007. Changing perspective on immunization against influenza. Vaccine 25:3062-3065.
16. Johansson, B. E., D. J. Bucher, and E. D. Kilbourne. 1989. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol. 63:1239-1246.
17. Johansson, B. E., B. Grajower, and E. D. Kilbourne. 1993. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 11:1037-1039.
18. Johansson, B. E., and E. D. Kilbourne. 1993. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J. Virol. 67:5721-5723.
19. Johansson, B. E., J. T. Matthews, and E. D. Kilbourne. 1998. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 16:1009-1015.
20. Johansson, B. E., T. M. Moran, and E. D. Kilbourne. 1987. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 84:6869-6873.
21. Johansson, B. E., B. A. Pokorny, and V. A. Tiso. 2002. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine 20:1670-1674.
22. Karber, G. 1931. Beitrag zur kollektiven behandlung pharmakologischer reihenversuche Exp. Pathol. Pharmakol. 162:480-483.
23. Kendal, A. P., F. M. Bozeman, and F. A. Ennis. 1980. Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Infect. Immun. 29:966-971.
24. Kilbourne, E. D. 1987. Influenza, p. 164-165. Plenum Publishing, New York, NY.
25. Kilbourne, E. D., B. E. Johansson, and B. Grajower. 1990. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 87:786-790.
26. Kilbourne, E. D., W. G. Laver, J. L. Schulman, and R. G. Webster. 1968. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J. Virol. 2:281-288.
27. Kilbourne, E. D., B. A. Pokorny, B. Johansson, I. Brett, Y. Milev, and J. T. Matthews. 2004. Protection of mice with recombinant influenza virus neuraminidase. J. Infect. Dis. 189:459-461.
28. Lakey, D. L., J. J. Treanor, R. F. Betts, G. E. Smith, J. Thompson, E. Sannella, G. Reed, B. E. Wilkinson, and P. F. Wright. 1996. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J. Infect. Dis. 174:838-841.
29. Lambre, C. R., H. Terzidis, A. Greffard, and R. G. Webster. 1991. An enzyme-linked lectin assay for sialidase. Clin. Chim. Acta 198:183-193.
30. Li, W., M. J. Moore, N. Vasilieva, J. Sui, S. K. Wong, M. A. Berne, M. Somasundaran, J. L. Sullivan, K. Luzuriaga, T. C. Greenough, H. Choe, and M. Farzan. 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450-454.
31. Madhun, A. S., L. R. Haaheim, M. V. Nilsen, and R. J. Cox. 2009. Intramuscular matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine 27:7367-7376.
32. Munster, V. J., E. de Wit, J. M. van den Brand, S. Herfst, E. J. Schrauwen, T. M. Bestebroer, D. van de Vijver, C. A. Boucher, M. Koopmans, G. F. Rimmelzwaan, T. Kuiken, A. D. Osterhaus, and R. A. Fouchier. 2009. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 325:481-483.
33. Palmer, D. F., W. R. Dowdle, M. T. Coleman, and G. C. Schild. 1975. Haemagglutination inhibition test, p. 25-62. In Advances laboratory techniques for influenza diagnosis: procedural guide. U.S. Department of Health, Education and Welfare, Atlanta, GA.
34. Powers, D. C., E. D. Kilbourne, and B. E. Johansson. 1996. Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin. Diagn. Lab. Immunol. 3:511-516.
35. Powers, D. C., G. E. Smith, E. L. Anderson, D. J. Kennedy, C. S. Hackett, B. E. Wilkinson, F. Volvovitz, R. B. Belshe, and J. J. Treanor. 1995. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J. Infect. Dis. 171:1595-1599.
36. Rimmelzwaan, G. F., M. Baars, E. C. Claas, and A. D. Osterhaus. 1998. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J. Virol. Methods 74:57-66.
37. Sandbulte, M. R., G. S. Jimenez, A. C. Boon, L. R. Smith, J. J. Treanor, and R. J. Webby. 2007. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4:e59.
38. Schulman, J. L., M. Khakpour, and E. D. Kilbourne. 1968. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J. Virol. 2:778-786.
39. Soundararajan, V., K. Tharakaraman, R. Raman, S. Raguram, Z. Shriver, V. Sasisekharan, and R. Sasisekharan. 2009. Extrapolating from sequence - the 2009 H1N1 'swine' influenza virus. Nat. Biotechnol. 27:510-513.
40. Sylte, M. J., and D. L. Suarez. 2009. Influenza neuraminidase as a vaccine antigen. Curr. Top. Microbiol. Immunol. 333:227-241.
41. Treanor, J. J., B. E. Wilkinson, F. Masseoud, J. Hu-Primmer, R. Battaglia, D. O'Brien, M. Wolff, G. Rabinovich, W. Blackwelder, and J. M. Katz. 2001. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737.
42. van den Brand, J. M., K. J. Stittelaar, G. van Amerongen, G. F. Rimmelzwaan, J. Simon, E. de Wit, V. Munster, T. Bestebroer, R. A. Fouchier, T. Kuiken, and A. D. Osterhaus. 2010. Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus. J. Infect. Dis. 201:993-999.
43. Wang, C. C., J. R. Chen, Y. C. Tseng, C. H. Hsu, Y. F. Hung, S. W. Chen, C. M. Chen, K. H. Khoo, T. J. Cheng, Y. S. Cheng, J. T. Jan, C. Y. Wu, C. Ma, and C. H. Wong. 2009. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc. Natl. Acad. Sci. U. S. A. 106:18137-18142.
44. Webster, R. G., W. G. Laver, and E. D. Kilbourne. 1968. Reactions of antibodies with surface antigens of influenza virus. J. Gen. Virol. 3:315-326.